Next Article in Journal
Gemcitabine-Induced Pseudocellulitis: A Case Report and Review of the Literature
Previous Article in Journal
Complete Resolution of Chylopericardium after Chemotherapy for Chronic Lymphocytic Leukemia
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Panitumumab-Induced Pulmonary Toxicity

1
Medical Oncology, Department of Oncology, McMaster University, Hamilton, ON, Canada
2
Juravinski Cancer Centre, 699 Concession Street, 4th Floor, Room 203, Hamilton, ON L8V 5C2, Canada
3
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(5), 700-702; https://doi.org/10.3747/co.26.5399
Submission received: 13 July 2019 / Revised: 7 August 2019 / Accepted: 5 September 2019 / Published: 1 October 2019

Abstract

Mutations in EGFR have been implicated in the pathogenesis of various types of cancer, and therefore antibody therapy directed against the epidermal growth factor receptor (egfr) is increasingly being used in the management of various cancers. Currently, anti-egfr antibodies are used mainly in the management of cancers of the head and neck and metastatic colorectal cancers. Because of this increasing use, we would like to inform the oncology community in North America of a rare, but life-threatening, toxicity associated with anti-egfr antibody therapy. Although cases in white and Japanese men have been documented, we present the first known North American report of panitumumab-induced pulmonary toxicity in a white woman.
Keywords: egfr; panitumumab; pulmonary toxicity; ards egfr; panitumumab; pulmonary toxicity; ards

Share and Cite

MDPI and ACS Style

Arora, R.; Kisiel, M.; MacColl, C. Panitumumab-Induced Pulmonary Toxicity. Curr. Oncol. 2019, 26, 700-702. https://doi.org/10.3747/co.26.5399

AMA Style

Arora R, Kisiel M, MacColl C. Panitumumab-Induced Pulmonary Toxicity. Current Oncology. 2019; 26(5):700-702. https://doi.org/10.3747/co.26.5399

Chicago/Turabian Style

Arora, Roochi, M. Kisiel, and C. MacColl. 2019. "Panitumumab-Induced Pulmonary Toxicity" Current Oncology 26, no. 5: 700-702. https://doi.org/10.3747/co.26.5399

APA Style

Arora, R., Kisiel, M., & MacColl, C. (2019). Panitumumab-Induced Pulmonary Toxicity. Current Oncology, 26(5), 700-702. https://doi.org/10.3747/co.26.5399

Article Metrics

Back to TopTop